If you or a loved one uses a generic drug - this is important: Certain brand pharmaceutical companies are blocking the ability of generic and biosimilar manufacturers to make more affordable, safe generic and biosimilar alternatives.
Generic companies need access to samples to conduct drug product development and bioequivalence studies necessary for FDA approval. Access delays to safe, affordable medicines are costing patients and taxpayers more than $5 billion each year.
It's time for Congress to put patients before profits and end this anti-competitive practice or "REMS Abuse" to increase prescription drug competition. Tell lawmakers to pass the CREATES Act (S. 340/H.R. 965).
Paid for by the Association for Accessible Medicines.
Thank you for taking action. Please encourage others to act by sharing on social media.